Nikolaos Tertipis

Nikolaos Tertipis

Auto-generated profile, based on publicly available information

Nikolaos Tertipis

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Oral Oncology
Verified
Journal Article
Closed access
Tina DalianisTina Dalianis
Tina Dalianis
NGNathalie Grün
Nathalie Grün
JKJana Koch
Jana Koch
AVAndrea Vlastos
Andrea Vlastos
NTNikolaos Tertipis
Nikolaos Tertipis
TRTorbjörn Ramqvist
Torbjörn Ramqvist

21 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NTNikolaos Tertipis
Nikolaos Tertipis
LHLinnea Haeggblom
Linnea Haeggblom
CNCecilia Nordfors
Cecilia Nordfors
NGNathalie Grün
Nathalie Grün
Anders NäsmanAnders Näsman
Anders Näsman
TRTorbjörn Ramqvist
Torbjörn Ramqvist
To examine LMP10 expression and its possible impact on clinical outcome in human papillomavirus (HPV) positive and HPV-negative tonsillar and base of tongue squamous cell carcinoma (TSCC and BOTSCC). Outcome is better in HPV-positive TSCC and BOTSCC compared to matching HPV-negative tumours, with roughly 80% vs. 40% 5-year disease free survival (DFS) with less aggressive treatment than today’s chemoradiotherapy. Since current treatment often results in harmful side effects, less intensive therapy, with sustained patient survival would be an attractive alternative. However, other markers together with HPV status are necessary to select patients and for this purpose LMP10 expression is investigated here in parallel to HPV status and clinical outcome. From 385 patients diagnosed between 2000 and 2007 at the Karolinska University Hospital, 278 formalin fixed paraffin embedded TSCC and BOTSCC biopsies, with known HPV DNA status, were tested for LMP10 nuclear and cytoplasmic expression (fraction of positive cells and staining intensity). The data was then correlated to clinical outcome. An absent/low compared to a moderate/high LMP10 nuclear fraction of positive cells was correlated to a better 3-year DFS in the HPV-positive group of patients (log-rank p = 0.005), but not in the HPV-negative group. In the HPV-negative group of patients, in contrast to the HPV-positive group, moderate/high LMP10 cytoplasmic fraction and weak/moderate/high LMP10 cytoplasmic intensity correlated to a better 3-year DFS (p = 0.003 and p = 0.001) and 3-year overall survival (p = 0.001 and 0.009). LMP10 nuclear expression in the HPV-positive group and LMP10 cytoplasmic expression in the HPV-negative group of patients correlated to better clinical outcome.

1 May 2014
Verified
Journal Article
Closed access
NTNikolaos Tertipis
Nikolaos Tertipis
LVLisa Villabona
Lisa Villabona
CNCecilia Nordfors
Cecilia Nordfors
Anders NäsmanAnders Näsman
Anders Näsman
TRTorbjörn Ramqvist
Torbjörn Ramqvist
Tina DalianisTina Dalianis
Tina Dalianis